系统性红斑狼疮炎症性肌肉骨骼表现的定义
该研究纳入112例SLE患者(排除RF和CCP阳性),其中88例有炎症性MSK症状、24例无症状,均行临床评估和双手腕超声。68%症状患者超声有炎症,而临床炎症仅38%(BILAG A/B)或32%(SLEDAI-MSK);27%为亚临床炎症,35%无临床或超声炎症。结论认为基于关节肿胀的疾病活动工具不能准确识别炎症,超声可发现大量有临床意义的炎症。
要点
- SLE伴MSK症状患者中68%超声有炎症,但仅38%符合BILAG A/B、32%符合SLEDAI-MSK。
- 27%患者存在亚临床炎症(超声异常但无临床肿胀关节),35%无临床或超声炎症。
- BILAG A/B和SLEDAI-MSK对超声确认炎症的敏感性低(56%和44%),特异性均89%。
核心结论
- 在伴MSK症状的SLE患者中,大部分有临床意义的客观炎症只能通过超声识别。
- 现有基于关节肿胀的疾病活动工具分类MSK狼疮不准确,不宜用于筛选临床试验、生物制剂治疗或达标治疗患者。
研究设计与样本
- 单中心研究,纳入112例SLE患者(排除RF和CCP阳性),其中88例连续有炎症性MSK症状、24例无症状对照。
- 所有患者行临床评估(BILAG、SLEDAI、关节计数、患者和医生VAS)、常规实验室检查及双手腕超声(滑膜炎和腱鞘炎,OMERACT定义)。
主要发现
- 症状患者中68%(60/88)超声有炎症(灰阶≥2和/或PD≥1或腱鞘炎),无症状患者中17%(4/23)超声有炎症。
- 症状患者中临床炎症按BILAG A或B定义占38%(34/88),按SLEDAI-MSK标准定义占32%(28/88)。
- BILAG A/B对超声确认炎症的敏感性56%(95%CI 41-69%),特异性89%(95%CI 72-96%)。
- SLEDAI-MSK标准对超声确认炎症的敏感性44%(95%CI 31-59%),特异性89%(95%CI 72-96%)。
- 炎症症状患者中27%(24/88)有亚临床炎症(超声异常但无临床肿胀关节),35%(31/88)无临床或超声炎症。
关键数值与推荐
- 超声炎症定义:灰阶≥2和/或PD≥1或腱鞘炎(OMERACT定义)。
- 临床炎症定义:BILAG A或B,或SLEDAI-MSK标准。
临床怎么用
- 对伴MSK症状的SLE患者,应使用超声评估炎症,以识别临床检查漏诊的亚临床炎症。
- 基于关节肿胀的BILAG和SLEDAI-MSK可能低估炎症,不宜单独用于临床试验筛选或达标治疗决策。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To define the prevalence and clinical associations of clinical and imaging definitions of synovitis in unselected SLE patients with musculoskeletal (MSK) symptoms. METHODS: 112 patients with SLE (excluding RF and CCP positive patients); 88 consecutive with inflammatory MSK symptoms and 24 asymptomatic SLE controls were recruited. Patients had clinical assessment (BILAG, SLEDAI, joint counts, patient and physician visual analogue score), routine laboratory tests and US of two hands and wrists (synovitis and tenosynovitis, OMERACT definitions). RESULTS: Overall, 68% (60/88) of symptomatic patients had US inflammation (grey scale ⩾ 2 and/or PD ⩾ 1 or tenosynovitis) compared with 17% (4/23) of asymptomatic patients. In symptomatic patients, clinical inflammation was seen defined by BILAG A or B in 38% (34/88) or defined by the SLEDAI-MSK criterion in 32% (28/88). BILAG A/B had sensitivity (95% CI) of 56% (41, 69%) and specificity of 89% (72, 96%) for US-confirmed inflammation. SLEDAI-MSK criterion had sensitivity of 44% (31, 59%) and specificity of 89% (72, 96%). In patients with inflammatory symptoms, 27% (24/88) had subclinical inflammation (abnormal US but no clinically swollen joints) and 35% (31/88) had no clinical or US inflammation. Subclinical tenosynovitis and PD were associated with significantly higher IgG, physician visual analogue score, tender joint count. CONCLUSION: In SLE patients with MSK symptoms, a large proportion of objective, clinically meaningful inflammation is only identifiable by US. The existing classification of MSK SLE using disease activity instruments based on joint swelling is inaccurate to guide patient selection for clinical trials, biologic therapy, or treat-to-target protocols.
引用
- Zayat AS, Mahmoud K, Md Yusof MY, et al. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology (Oxford). 2019. PMID: 30265343. doi:10.1093/rheumatology/key277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。